News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,087 Results
Type
Article (40080)
Company Profile (252)
Press Release (656755)
Section
Business (205163)
Career Advice (2023)
Deals (35544)
Drug Delivery (112)
Drug Development (81403)
Employer Resources (170)
FDA (16289)
Job Trends (14905)
News (347109)
Policy (33138)
Tag
Academia (2559)
Alliances (49622)
Alzheimer's disease (1323)
Approvals (16270)
Artificial intelligence (201)
Bankruptcy (359)
Best Places to Work (11673)
Biotechnology (177)
Breast cancer (226)
Cancer (1722)
Cardiovascular disease (133)
Career advice (1686)
CAR-T (122)
Cell therapy (355)
Clinical research (65577)
Collaboration (664)
Compensation (370)
COVID-19 (2585)
C-suite (160)
Data (1636)
Diabetes (226)
Diagnostics (6309)
Earnings (85852)
Employer resources (147)
Events (111526)
Executive appointments (566)
FDA (17194)
Funding (608)
Gene therapy (250)
GLP-1 (727)
Government (4645)
Healthcare (18933)
Infectious disease (2696)
Interviews (312)
IPO (16509)
Job creations (3672)
Job search strategy (1437)
Layoffs (445)
Legal (7974)
Lung cancer (256)
Manufacturing (245)
Medical device (13341)
Medtech (13346)
Mergers & acquisitions (19413)
Metabolic disorders (608)
Neuroscience (1731)
NextGen: Class of 2025 (6542)
Non-profit (4522)
Northern California (2092)
Obesity (344)
Opinion (197)
Patents (162)
People (57122)
Phase I (20386)
Phase II (28856)
Phase III (21557)
Pipeline (711)
Postmarket research (2587)
Preclinical (8608)
Radiopharmaceuticals (242)
Rare diseases (325)
Real estate (5941)
Regulatory (22236)
Research institute (2330)
Resumes & cover letters (351)
Southern California (1795)
Startups (3592)
United States (18477)
Vaccines (618)
Weight loss (254)
Date
Last 7 days (596)
Last 30 days (2434)
Last 365 days (34547)
2025 (4454)
2024 (35388)
2023 (40214)
2022 (51351)
2021 (55938)
2020 (54383)
2019 (46975)
2018 (35353)
2017 (32307)
2016 (31746)
2015 (37801)
2014 (31568)
2013 (26558)
2012 (28763)
2011 (29440)
2010 (27552)
Location
Africa (735)
Arizona (212)
Asia (37780)
Australia (6207)
California (4769)
Canada (1732)
China (395)
Colorado (217)
Connecticut (230)
Europe (81431)
Florida (689)
Georgia (165)
Illinois (455)
Indiana (261)
Japan (122)
Maryland (741)
Massachusetts (3609)
Michigan (198)
Minnesota (335)
New Jersey (1349)
New York (1359)
North Carolina (837)
Northern California (2092)
Ohio (174)
Pennsylvania (1102)
South America (1108)
Southern California (1795)
Texas (701)
Utah (143)
Washington State (469)
697,087 Results for "novo nordisk canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s
blockbuster
Hemlibra.
February 7, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
Despite Doubled Wegovy Sales, Novo Executives Confront Analysts’ Insatiable Appetite
Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.
February 5, 2025
·
2 min read
·
Annalee Armstrong
GLP-1
Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon technology platform in an effort to find novel GLP-1 candidates with reduced dosing frequency.
November 4, 2024
·
1 min read
·
Annalee Armstrong
IRA
With Wegovy, Ozempic on the Line, Novo Asks Court to Speed Up IRA Complaint
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the second round of the IRA drug price negotiation program, even as the pharma challenges the program.
January 29, 2025
·
1 min read
·
Tristan Manalac
GLP-1
EMA to Investigate Eye Risk for Novo’s Ozempic: Reuters
Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have strengthened the link between Novo Nordisk’s blockbuster GLP-1 and a rare eye disease.
December 18, 2024
·
2 min read
·
Annalee Armstrong
Legal
Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug
Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.
February 18, 2025
·
1 min read
·
Annalee Armstrong
Opinion
Why Is Novo Outperforming Lilly Despite Having Inferior GLP-1 Products?
Novo Nordisk’s GLP-1s outsell Eli Lilly’s thanks to its superior marketing. Here’s how.
January 3, 2025
·
6 min read
·
Gary Stibel
Layoffs
Novo Partner Omega Waves Bankruptcy Flag from Sinking Ship
Just over a year after striking an obesity deal with Novo Nordisk, an SEC filing shows Flagship Pioneering spinout Omega Therapeutics is days away from bankruptcy and will lay off up to 17 employees.
February 4, 2025
·
1 min read
·
Kate Goodwin
Diabetes
Novo Launches Citizen Petition to Block Compounded Victoza
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, the type 2 diabetes injection it sells as Victoza.
January 6, 2025
·
2 min read
·
Tristan Manalac
Weight loss
After Unforced Error, Novo Execs Try to Boost CagriSema Sentiment—Without Hard Numbers
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, executives are taking another look at the data but steering clear of making hard bets.
February 7, 2025
·
3 min read
·
Annalee Armstrong
1 of 69,709
Next
